Biogen Idec Inc. said Monday that its multiple sclerosis pill, Tecfidera, has been approved by regulators as a first-line treatment for people with the most common form of MS in Europe.
The drug got US approval last March. In November, European officials said that Tecfidera would have 10 years of regulatory data exclusivity if the drug got final approval. (The company has equivalent protection in the US.)
In a statement included in Monday’s press release, Biogen Idec chief executive George A. Scangos said: “Tecfidera exemplifies our commitment to deliver innovative therapies that help people living with serious diseases. We already have seen Tecfidera’s significant impact on transforming the standard of care for MS where it is available and are excited to quickly bring its benefits to patients in the EU as well.”